Optimizing Treatment with Tyrosine Kinase Inhibitors: Focus on Dosing Schedules
Could thinking outside the box in regards to the way these agents are dosed, provide a new, more efficient equilibrium between toxicity and efficacy?
In this session, we will be focusing on one of the TKIs, namely sunitinib, to present a proof of principle that modulation of the dosing scheduling could potentially broaden the therapeutic window. The whole trajectory, from preclinical work to clinical application is presented; initially the effect of this alternative dosing schedule observed in vitro on cancer cells, followed by the effect in vivo on tumors growing on the chorioallantoic membrane (CAM) of the chicken embryo and finally the bedside translation of these preclinical data in the context of a (phase I ) clinical trial. The results, regarding the observed side effects and preliminary efficacy data of patients with advanced cancer treated with this alternative scheduling will be presented.